MX366607B - Espiro-oxazolonas. - Google Patents

Espiro-oxazolonas.

Info

Publication number
MX366607B
MX366607B MX2016009501A MX2016009501A MX366607B MX 366607 B MX366607 B MX 366607B MX 2016009501 A MX2016009501 A MX 2016009501A MX 2016009501 A MX2016009501 A MX 2016009501A MX 366607 B MX366607 B MX 366607B
Authority
MX
Mexico
Prior art keywords
oxazolones
disorders
spiro
present
vasopressin
Prior art date
Application number
MX2016009501A
Other languages
English (en)
Other versions
MX2016009501A (es
Inventor
Dolente Cosimo
Schnider Patrick
Runtz-Schmitt Valerie
Fasching Bernhard
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016009501A publication Critical patent/MX2016009501A/es
Publication of MX366607B publication Critical patent/MX366607B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

La presente invención proporciona espiro-oxazolonas, que actúan como moduladores del receptor V1a, y en particular, como antagonistas del receptor V1a, su fabricación, composiciones farmacéuticas que los contienen y a su uso como medicamentos. Los presentes compuestos son útiles como agentes terapéuticos que actúan de manera periférica y central en condiciones de secreción inadecuada de vasopresina, ansiedad, trastornos depresivos, trastorno obsesivo-compulsivo, trastornos del espectro autista, esquizofrenia, comportamiento agresivo y trastornos del sueño por cambio de fase, en particular, descompensación horaria.
MX2016009501A 2014-02-20 2015-02-17 Espiro-oxazolonas. MX366607B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14155965 2014-02-20
PCT/EP2015/053246 WO2015124541A1 (en) 2014-02-20 2015-02-17 Spiro-oxazolones

Publications (2)

Publication Number Publication Date
MX2016009501A MX2016009501A (es) 2016-10-26
MX366607B true MX366607B (es) 2019-07-16

Family

ID=50115765

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009501A MX366607B (es) 2014-02-20 2015-02-17 Espiro-oxazolonas.

Country Status (11)

Country Link
US (1) US9828385B2 (es)
EP (1) EP3107916B1 (es)
JP (1) JP6480947B2 (es)
KR (1) KR20160124105A (es)
CN (1) CN105793266B (es)
AR (1) AR099475A1 (es)
CA (1) CA2929488A1 (es)
MX (1) MX366607B (es)
RU (1) RU2016135089A (es)
TW (1) TW201600522A (es)
WO (1) WO2015124541A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases
US10968177B2 (en) 2016-10-10 2021-04-06 Bristol-Myers Squibb Company Tricyclic sulfones as RORγ modulators
WO2019224032A1 (en) * 2018-05-25 2019-11-28 Basf Se Use of compositions comprising a solvent mixture for avoiding pattern collapse when treating patterned materials with line-space dimensions of 50 nm or below
CN109305927A (zh) * 2018-10-31 2019-02-05 抚顺顺能化工有限公司 环己酮氰醇的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050652A1 (ja) * 2002-11-29 2004-06-17 Banyu Pharmaceutical Co., Ltd. 新規アゾール誘導体
EP1885713A1 (en) * 2005-05-18 2008-02-13 Pfizer Limited 1, 2, 4 -triazole derivatives as vasopressin antagonists
EP2076517A1 (en) * 2006-09-22 2009-07-08 Janssen Pharmaceutica N.V. Spiro benzazepines as vasopressin antagonists
WO2008084005A1 (en) * 2007-01-12 2008-07-17 F. Hoffmann-La Roche Ag Spiropiperidine glycinamide derivatives
EA017648B1 (ru) * 2007-09-14 2013-02-28 Орто-Макнейл-Янссен Фармасьютикалз, Инк. 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
WO2012077655A1 (ja) * 2010-12-07 2012-06-14 塩野義製薬株式会社 Ｇｐｒ１１９アゴニスト活性を有するスピロ誘導体
PL3083633T3 (pl) * 2013-12-19 2018-04-30 F.Hoffmann-La Roche Ag Spirooksazolony
US10405278B2 (en) * 2014-10-31 2019-09-03 Qualcomm Incorporated Low power scheduling

Also Published As

Publication number Publication date
CA2929488A1 (en) 2015-08-27
KR20160124105A (ko) 2016-10-26
AR099475A1 (es) 2016-07-27
TW201600522A (zh) 2016-01-01
JP6480947B2 (ja) 2019-03-13
HK1223922A1 (zh) 2017-08-11
WO2015124541A1 (en) 2015-08-27
JP2017507144A (ja) 2017-03-16
CN105793266B (zh) 2019-02-12
EP3107916A1 (en) 2016-12-28
MX2016009501A (es) 2016-10-26
US20160355522A1 (en) 2016-12-08
RU2016135089A (ru) 2018-03-23
CN105793266A (zh) 2016-07-20
EP3107916B1 (en) 2019-03-20
US9828385B2 (en) 2017-11-28

Similar Documents

Publication Publication Date Title
MY177031A (en) Tetrahydropyridopyrazines modulators of gpr6
MX351165B (es) Antagonistas de trpv1.
CL2014002334A1 (es) Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras.
GEAP201814515A (en) 4-oxo-3,4-dihydro-1,2,3 -benzotriazines modulators of gpr139
NZ730334A (en) Substituted 2-azabicycles and their use as orexin receptor modulators
EA201590932A1 (ru) Композиции, содержащие вортиоксетин и донепезил
MY184366A (en) Pyrazines modulators of gpr6
IL253271A0 (en) Lingo-1 antagonists and uses for the treatment of demyelinating disorders
EP3194027C0 (en) COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC DISORDERS
CL2016002839A1 (es) Derivados de carboxamida
EP3655036C0 (en) COMPOSITIONS FOR THE TREATMENT OF STRESS-RELATED DISORDERS
GB201401086D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EA026371B8 (ru) Индолкарбонитрилы в качестве модуляторов рецептора андрогенов
PH12016500919A1 (en) Spiro-oxazolones
MX2016009501A (es) Espiro-oxazolonas.
EP3288578B8 (en) Compositions for colon cleansing and the treatment of gastrointestinal disorders
MX2016001940A (es) Antagonistas de v1a para tratar trastornos del sueño por cambio de fase.
PH12017500891A1 (en) Spiro-thiazolones
TWI561235B (en) Increase of protein synthesis ameliorates synaptopathy-related neurological disorders
SG10201803880TA (en) Stable compositions of neuroactive peptides
NZ723269A (en) Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
TH149082A (th) องค์ประกอบชนิดใหม่, การเตรียมของสารเหล่านี้ และการใช้ของสารเหล่านี้สำหรับผลิตโพลีเอไมด์ที่เป็นตัวหล่อ

Legal Events

Date Code Title Description
FG Grant or registration